A TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是验证一种假设，即在重症肌无力（mg）的初始治疗中，霉酚酸酯（2.5 g/d）联合强的松（20 mg/d）比单独使用强的松能更好地控制体征和症状。为期6个月的开放标签延长试验将提供关于2.5- 3g /d剂量MM的安全性和耐受性的进一步信息，并将提供一些关于泼尼松可以逐渐减少甚至停药的频率的初步信息。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this study is to test the hypothesis that mycophenolate mofetil (2.5 g/d) in combination with prednisone (20 mg/d) provides better control of signs and symptoms than prednisone alone in the initial management of myasthenia gravis (MG). A 6 month open-label extension will supply further information about the safety and tolerability of MM at doses ranging from 2.5-3 g/d, and will give some preliminary information about the frequency with which prednisone can be tapered or even discontinued in patients maintained on MM.